Biosign Receives Conditional Approval for Listing on TSX Venture Exchange

TORONTO, Aug. 27 /PRNewswire-FirstCall/ - Biosign Technologies Inc. (CNSX: BIO) today announced that the Company has filed, on SEDAR, its Listing Statement following the receipt of the TSX Venture Exchange's (the "Exchange") conditional approval for the listing of the Company's securities. The listing is subject to the Company fulfilling certain requirements of the Exchange in accordance with the terms of its conditional approval letter dated August 24, 2010.

The Company expects to file with the Exchange, before the end of next week, the final documentation requested in the Exchange's conditional approval letter and, pending review and acceptance by the Exchange of such documentation, the Company anticipates trading on its securities to commence next week on a day to be determined by the Exchange, under the trading symbol "BIO".

"Our listing on the TSX Venture Exchange is another important milestone in our growth and development," said Radu Leca, President of the Company. "We believe that this listing will provide the company and its shareholders with many advantages, including greater visibility and enhanced market access for Canadian and international investors."

TSX Venture Exchange is Canada's public venture capital marketplace, offering investors a well-regulated market for making venture capital investments. In November 1999, Vancouver and Alberta Stock Exchanges joined together to form the Canadian Venture Exchange (CDNX). The Canadian Dealing Network, Winnipeg Stock Exchange and junior equities portion of the Montreal Exchange subsequently merged with CDNX, which later became TSX Venture Exchange.

About Biosign Technologies Inc.

Biosign Technologies Inc. (CNSX: BIO) provides biomedical and intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose and medication. The core technology combines measurement, analysis and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com.

The CNSX has neither approved nor disapproved the contents of this press release.

SOURCE Biosign Technologies Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED